solitärer fibröser Tumor der Leber
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/9/7/6/3/6/12957_2017_1102_Fig1_HTML_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/9/7/6/3/7/12957_2017_1102_Fig2_HTML_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/9/7/6/3/8/12957_2017_1102_Fig3_HTML_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/9/7/6/3/9/12957_2017_1102_Fig4_HTML_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/1/9/4/0/5/b27d2b77f39606d83e7b42e316a728_big_gallery_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/1/9/4/0/6/40792_2019_625_Fig1_HTML_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/1/9/4/0/7/40792_2019_625_Fig2_HTML_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/1/9/4/0/9/12957_2010_Article_789_Fig1_HTML_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/1/9/4/1/0/12957_2006_Article_236_Fig1_HTML_thumb.jpg)
![](https://pacs.de/sites/default/files/pictures/thumbs/data.pacs.de/1/1/9/4/1/1/13000_2011_Article_493_Fig1_HTML_thumb.jpg)
Hepatic solitary fibrous tumors (hepatic SFTs) are rare mesenchymal tumors.
Epidemiology
Fewer than 60 cases have been reported in the literature. Female predominance (~70%). There is a mean age of 52 years at presentation, but a wide range of incidence (16-84 years).
Clinical presentation
If the patient is symptomatic at all, the presentation is usually mild and nonspecific, including abdominal pain, bloating, dyspepsia.
Hypoglycemia has been reported in some patients, presumably a paraneoplastic syndrome.
Pathology
Microscopic appearance
These tumors demonstrate high cellular proliferation of spindle cells arranged in a storiform pattern.
Immunophenotype
- CD34: positive
- vimentin: positive
- Bcl-2: positive
- SM-actin: negative
Radiographic features
A prospective diagnosis of hepatic SFT is not usually possible because imaging features are usually relatively nonspecific. Intratumoral necrosis has been reported in a few lesions. Benign tumors cannot currently be reliably be differentiated from malignant tumors.
CT
- nonspecific enhancing mass
- heterogeneous enhancement has been reported
MRI
- T1: hypointense
- T2: heterogeneous appearance
- T1 C+ (Gd): heterogeneous enhancement, depending on the relative amounts of cellular and collagen components
Nuclear Medicine
- FDG-PET: avid FDG uptake
Treatment and prognosis
Most recorded hepatic SFTs are benign, but it is possible for them to exhibit malignant behavior . Some think that malignant foci may exist in biopsy-benign tumors, and the risk of malignancy is estimated at ~10% .
Given the rarity of the tumor, no standard treatment exists. Partial hepatectomy has been performed for some lesions, given the concern for occult malignancy.
Differential diagnosis
- hepatocellular carcinoma
- metastatic GIST
- hepatic leiomyoma
- hepatic angiomyolipoma
- inflammatory myofibroblastic tumor of the liver
- hemangiopericytoma
Siehe auch:
![Click für weniger anzeigen](/sites/all/modules/pacs/tools/imgs/collapse_up.png)
![](/sites/all/modules/pacs/tools/imgs/Iris_color_40.png)